A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)
Clinical trial NCT02018861 · COMPLETED
Trial details
- NCT number
- NCT02018861
- Sponsor
- Incyte Corporation
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-09-22
- Primary completion
- 2021-04-12
- Enrollment
- 88
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.